Incheon, South Korea

Heon-Jong Lee


 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Heon-Jong Lee: Innovator in Cell Protection

Introduction

Heon-Jong Lee is a notable inventor based in Incheon, South Korea. He has made significant contributions to the field of cell protection, particularly concerning kidney and liver health. With a total of three patents to his name, Lee's work focuses on innovative compositions that utilize cyclo histidine-proline as an active ingredient.

Latest Patents

Lee's latest patents include a cell-protecting composition that contains cyclo histidine-proline (Cyclo His-Pro, CHP) as an active ingredient. This composition has demonstrated an excellent protective effect against damage and toxicity to kidney and liver cells caused by various factors. The composition is particularly useful in treating subjects with kidney and liver diseases or damages. Another patent also highlights a similar composition for cell protection, emphasizing the effectiveness of cyclo histidine-proline in safeguarding these vital organs.

Career Highlights

Heon-Jong Lee is currently associated with Novmetapharma Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its potential applications in medical treatments and therapies aimed at protecting organ health.

Collaborations

Lee collaborates with esteemed colleagues, including Hoe-Yune Jung and Jong-Su Jeon, who contribute to his research endeavors and innovations in the field.

Conclusion

Heon-Jong Lee's innovative work in cell protection showcases the potential of cyclo histidine-proline in medical applications. His contributions are paving the way for advancements in treating kidney and liver diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…